Compare STLA & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STLA | RMD |
|---|---|---|
| Founded | 2021 | 1989 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6B | 36.4B |
| IPO Year | N/A | 1995 |
| Metric | STLA | RMD |
|---|---|---|
| Price | $11.96 | $252.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $11.99 | ★ $292.27 |
| AVG Volume (30 Days) | ★ 12.5M | 893.0K |
| Earning Date | 07-29-2025 | 01-29-2026 |
| Dividend Yield | ★ 4.90% | 0.95% |
| EPS Growth | N/A | ★ 29.59 |
| EPS | N/A | ★ 9.77 |
| Revenue | ★ $171,605,402,237.00 | $5,257,400,000.00 |
| Revenue This Year | N/A | $9.85 |
| Revenue Next Year | $5.33 | $7.32 |
| P/E Ratio | ★ N/A | $25.82 |
| Revenue Growth | N/A | ★ 9.36 |
| 52 Week Low | $8.39 | $199.92 |
| 52 Week High | $14.28 | $293.81 |
| Indicator | STLA | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 63.15 | 48.94 |
| Support Level | $11.71 | $250.37 |
| Resistance Level | $12.15 | $259.99 |
| Average True Range (ATR) | 0.25 | 5.54 |
| MACD | 0.10 | 0.57 |
| Stochastic Oscillator | 87.50 | 63.20 |
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.